Duffau Hugues
Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors", National Institute for Health and Medical Research (INSERM), U1191 Laboratory, Institute of Functional Genomics, University of Montpellier, Montpellier, France.
Front Oncol. 2022 Jul 5;12:947933. doi: 10.3389/fonc.2022.947933. eCollection 2022.
Early maximal surgical resection is the first treatment in diffuse low-grade glioma (DLGG), because the reduction of tumor volume delays malignant transformation and extends survival. Awake surgery with intraoperative mapping and behavioral monitoring enables to preserve quality of life (QoL). However, because of the infiltrative nature of DLGG, relapse is unavoidable, even after (supra)total resection. Therefore, besides chemotherapy and radiotherapy, the question of reoperation(s) is increasingly raised, especially because patients with DLGG usually enjoy a normal life with long-lasting projects. Here, the purpose is to review the literature in the emerging field of iterative surgeries in DLGG. First, long-term follow-up results showed that patients with DLGG who underwent multiple surgeries had an increased survival (above 17 years) with preservation of QoL. Second, the criteria guiding the decision to reoperate and defining the optimal timing are discussed, mainly based on the dynamic intercommunication between the glioma relapse (including its kinetics and pattern of regrowth) and the reactional cerebral reorganization-i.e., mechanisms underpinning reconfiguration within and across neural networks to enable functional compensation. Third, how to adapt medico-surgical strategy to this individual spatiotemporal brain tumor interplay is detailed, by considering the perpetual changes in connectome. These data support early reoperation in recurrent DLGG, before the onset of symptoms and before malignant transformation. Repeat awake resection(s) should be integrated in a global management including (neo)adjuvant medical treatments, to enhance long-lasting functional and oncological outcomes. The prediction of potential and limitation of neuroplasticity at each step of the disease must be improved to anticipate personalized multistage therapeutic attitudes.
早期最大程度手术切除是弥漫性低级别胶质瘤(DLGG)的首选治疗方法,因为肿瘤体积的减小可延缓恶性转化并延长生存期。术中进行图谱绘制和行为监测的清醒手术能够保留生活质量(QoL)。然而,由于DLGG具有浸润性,即使在(超)全切除术后复发也难以避免。因此,除了化疗和放疗外,再次手术的问题日益受到关注,特别是因为DLGG患者通常能够正常生活并拥有长期规划。在此,目的是回顾DLGG迭代手术这一新兴领域的文献。首先,长期随访结果表明,接受多次手术的DLGG患者生存期延长(超过17年)且生活质量得以保留。其次,主要基于胶质瘤复发(包括其动力学和再生长模式)与反应性脑重组之间的动态相互作用,即神经网络内部和之间重新配置以实现功能补偿的机制,讨论了指导再次手术决策和确定最佳时机的标准。第三,通过考虑连接组的持续变化,详细阐述了如何使药物和手术策略适应这种个体时空性脑肿瘤的相互作用。这些数据支持在复发性DLGG出现症状之前和恶性转化之前尽早进行再次手术。重复清醒切除术应纳入包括(新)辅助药物治疗在内的整体管理中,以提高长期功能和肿瘤学疗效。必须改善对疾病各阶段神经可塑性的潜力和局限性的预测,以预期个性化的多阶段治疗方案。